|
1. |
Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic Proteins |
|
Clinical Pharmacokinetics,
Volume 44,
Issue 4,
2005,
Page 331-347
Iftekhar Mahmood,
Martin D Green,
Preview
|
PDF (257KB)
|
|
摘要:
With an increasing number of therapeutic proteins moving into preclinical and clinical development, pharmacokinetic factors play an important role in the development of these macromolecules. It is also important that the pharmacokinetic evaluation of these compounds be done as accurately as possible. For macromolecules, evaluation of pharmacokinetic parameters is often complicated by a number of factors. Bioanalytical methods are essential for any pharmacokinetic study, but for many therapeutic proteins the immunoassay and bioassay methodologies are often nonspecific and sometimes the estimation of pharmacokinetic parameters becomes assay dependent.In vivobinding proteins, metabolites and antibody formation may also interfere with bioanalytical methodologies and thus may have significant impact on the pharmacokinetics of therapeutic proteins. There are also difficulties in identifying and quantifying metabolites as well as the binding of therapeutic proteins to endogenous proteins. Some macromolecules exhibit species specificity that complicates the preclinical pharmacological and toxicological evaluation of these compounds. Antibody formation is a particular problem in the preclinical evaluation of therapeutic proteins. Changes in structure or sequence of protein molecules (glycosylation or pegylation) may cause changes in the pharmacokinetics of these compounds. The size of therapeutic proteins may become a hindrance for absorption. Low absorption of intact molecules across biological membranes frequently occurs. Other factors that may affect the pharmacokinetics of a therapeutic protein are immunogenicity, presence of endogenous protein, time of drug administration, and rate and site of drug delivery. The relationship between pharmacokinetics and pharmacodynamics of therapeutic proteins is complex and in most cases is unclear. In many cases the mechanism and site of action are unknown for these compounds.
ISSN:0312-5963
出版商:ADIS
年代:2005
数据来源: ADIS
|
2. |
Role of Cytochrome P450 Activity in the Fate of Anticancer Agents and in Drug ResistanceFocus on Tamoxifen, Paclitaxel and Imatinib Metabolism |
|
Clinical Pharmacokinetics,
Volume 44,
Issue 4,
2005,
Page 349-366
Bertrand Rochat,
Preview
|
PDF (299KB)
|
|
摘要:
Although activity of cytochrome P450 isoenzymes (CYPs) plays a major role in the fate of anticancer agents in patients, there are relatively few clinical studies that evaluate drug metabolism with therapeutic outcome. Nevertheless, many clinical reports in various non-oncology fields have shown the dramatic importance of CYP activity in therapeutic efficacy, safety and interindividual variability of drug pharmacokinetics. Moreover, variability of drug metabolism in the liver as well as in cancer cells must also be considered as a potential factor mediating cancer resistance.This review underlines the role of drug metabolism mediated by CYPs in pharmacokinetic variability, drug resistance and safety. As examples, biotransformation pathways of tamoxifen, paclitaxel and imatinib are reviewed.This review emphasises the key role of therapeutic drug monitoring as a complementary tool of investigation toin vitrodata. For instance, pharmacokinetic data of anticancer agents have not often been published within subpopulations of patients who show ultra-rapid, extensive or poor metabolism (e.g. due to CYP2D6 and CYP2C19 genotypes).Besides kinetic variability in the systemic circulation, induction of CYP activity may participate in creating drug resistance by speeding up the cancer agent degradation specifically in the target cells. For one cancer agent, various mechanisms of resistance are usually identified within different cell clones. This review also tries to emphasise that drug resistance mediated by CYP activity in cancer cells should be taken into consideration to a greater degree.The unequivocal identification of the metabolising enzymes involved in clinical conditions will eventually allow improvement and individualisation of anticancer agent therapy, i.e. drug dosage and selection. In addition, a more complete understanding of the metabolism of anticancer agents will assist in the prediction of drug-drug interactions, as anticancer agent combinations are becoming more prevalent.
ISSN:0312-5963
出版商:ADIS
年代:2005
数据来源: ADIS
|
3. |
Pharmacokinetic/Pharmacodynamic Relationships of Asparaginase FormulationsThe Past, the Present and Recommendations for the Future |
|
Clinical Pharmacokinetics,
Volume 44,
Issue 4,
2005,
Page 367-393
Vassilios I Avramis,
Eduard H Panosyan,
Preview
|
PDF (570KB)
|
|
摘要:
The discovery of the tumour-inhibitory properties of asparaginase began 50 years ago with the observation that guinea-pig serum-treated lymphoma-bearing mice underwent rapid and often complete regression. Soon afterwards, the asparaginase of bacterial origin was isolated. The asparaginases of bacterial origin induce anti-asparaginase neutralising antibodies in a large proportion of patients (44–60%), thus negating the specific enzymatic activity and resulting in failure of the target amino acid deamination in serum. There is immunological cross-reaction between the antibodies against various formulations of nativeEscherichia coli-asparaginase and polyethylene glycol (PEG)-asparaginases, but not toErwiniaasparaginase, as suggested by laboratory preclinical findings. This evidence was strongly inferred from the interim analyses in the Children’s Cancer Group (CCG)-1961 study. Thus, anti-E. colior PEG-asparaginase antibodies seropositive patients may benefit from theErwiniaasparaginase.The inter-relationships between asparaginase activity, asparagine (ASN) and glutamine deamination remain largely unexplored in patients. Studies have shown that ASN depletion is insufficient to induce apoptosis in T lymphoblastsin vitroand that the inhibitory concentration of CEM T-cell line is correlated with the asparaginase concentration responsible for 50% glutamine deamination. The optimal catalysis of ASN and glutamine deamination in serum by asparaginase induces apoptosis of leukaemic lymphoblasts. The percentage of ASN and glutamine deamination was predicted by asparaginase activity. Asparaginase activity of 0.1 IU/mL provided insufficient depletion of both amino acids in high-risk acute lymphoblastic leukaemia (ALL) patients. With increasing glutamine deamination, mean asparaginase activities and percentages of post-treatment samples with effective ASN depletion (<3 μmol/L) increase. Both glutamine and ASN deamination are predicted by asparaginase activity. Further population analyses resulted in identification of sigmoid relationships between asparaginase levels and post-treatment glutamine and ASN deamination.Furthermore, pharmacodynamic analyses strongly suggested that ≥90% deamination of glutamine must occur before optimal ASN deamination takes place, due to thede novoASN biosynthesis by the liver. These pharmacodynamic results from the best-fit population pharmacokinetic/pharmacodynamic model obtained from nonlinear mixed effects model pharmacodynamic analyses for standard-risk ALL patients are similar. These analyses produced the following results: (i) asparaginase activity ≤0.4 IU/mL provided insufficient deamination of ASN, whereas >0.4–0.7 IU/mL was required for optimal (90%) ASN and glutamine deamination; and (ii) deamination of glutamine is dependent on asparaginase activity and it correlates with enhanced serum ASN deamination. Thus, glutamine deamination enhances asparaginase efficacy in ALL patients. Deamination of ASN ≥90% of control or ASN concentration <3 μmol/L may be associated with improved survival in this subset of patients. Our findings support the pharmacodynamic mechanism of PEG-asparaginase for disease control in ALL patients. These results taken together strongly support new experimental approaches for application of population pharmacokinetic/pharmacodynamic analyses to further enhance survival of leukaemia patients.
ISSN:0312-5963
出版商:ADIS
年代:2005
数据来源: ADIS
|
4. |
Pharmacokinetics of Famotidine in Infants |
|
Clinical Pharmacokinetics,
Volume 44,
Issue 4,
2005,
Page 395-406
Larissa A Wenning,
M Gail Murphy,
Laura P James,
Jeffrey L Blumer,
James D Marshall,
John Baier,
Ann O Scheimann,
Deborah L Panebianco,
Ling Zhong,
Roy Eisenhandler,
Kuang C Yeh,
Gregory L Kearns,
Preview
|
PDF (235KB)
|
|
摘要:
BackgroundAlthough famotidine pharmacokinetics are similar in adults and children older than 1 year of age, they differ in neonates owing to developmental immaturity in renal function. Little is currently known about the pharmacokinetics of famotidine in infants aged between 1 month and 1 year, a period when renal function is maturing.ObjectiveTo characterise the pharmacokinetics of famotidine in infants.DesignThis was a two-part multicentre study with both single dose (Part I, open-label) and multiple dose (Part II, randomised) arms.PatientsThirty-six infants (20 females and 16 males) who required treatment with famotidine and who had an indwelling arterial or venous catheter for reasons unrelated to the study.MethodsInfants in Part I were administered a single dose of famotidine 0.5 mg/kg; the dose was intravenous or oral according to the judgement of the attending physician. Infants receiving 0.5 mg/kg intravenously were divided into two groups by age, and pharmacokinetic parameters in infants 0–3 months and >3 to 12 months of age were compared. Infants in Part II were randomised to one of the following treatments: 0.25 mg/kg/dose intravenously or 0.5 mg/kg/dose orally on day 1 and subsequent days, or 0.25 mg/kg/dose intravenously or 0.5 mg/kg/dose orally on day 1 followed by doses of either 0.5 mg/kg/dose intravenously or 1 mg/kg/dose orally on subsequent days. From day 2 onwards, age-adjusted dose administration regimens (once daily in infants <3 months of age and every 12 hours in infants >3 months of age) were used; the total number of famotidine doses ranged from 3 to 11 and the total number of days of dose administration ranged from two to eight.ResultsIn infants <3 months of age, plasma and renal clearance of famotidine were decreased compared with infants >3 months of age. Pharmacokinetic parameters for the older infants (i.e. those >3 months) were similar to those previously reported for children and adults. Approximate dose-proportionality, no accumulation on multiple dosing and an estimated bioavailability similar to adult values were also observed.ConclusionA short course of famotidine therapy in infants appears generally well tolerated, and the characteristics of famotidine pharmacokinetics during the first year of life are explained to a great degree by the development of renal function, the primary route of elimination for this drug.
ISSN:0312-5963
出版商:ADIS
年代:2005
数据来源: ADIS
|
5. |
Topiramate Pharmacokinetics in Children and Adults with EpilepsyA Case-Matched Comparison Based on Therapeutic Drug Monitoring Data |
|
Clinical Pharmacokinetics,
Volume 44,
Issue 4,
2005,
Page 407-416
Dina Battino,
Danilo Croci,
Alessandro Rossini,
Sara Messina,
Daniela Mamoli,
Emilio Perucca,
Preview
|
PDF (243KB)
|
|
摘要:
ObjectiveTo compare the steady-state pharmacokinetics of topiramate in a large population of children and adults with epilepsy in a therapeutic drug monitoring setting.Study designRetrospective, case-matched pharmacokinetic evaluation.PatientsSeventy children (aged 1–17 years) with epilepsy and 70 adult controls (aged 18–65 years) with epilepsy, matched for sex and comedication.MethodsTopiramate apparent oral clearance (CL/F) values were calculated from steady-state serum concentrations in children and compared with those determined in controls. Comparisons were made by means of the Mann-Whitney’s U-test, or the Kruskal-Wallis test in the case of multiple comparisons. A linear regression model was used to assess potential correlation of CL/F values with age. To investigate the influence of different variables on the variability in topiramate CL/F values, a multiple regression model was developed.ResultsIn the absence of enzyme-inducing comedication, mean topiramate CL/F was 42% higher in children than in adults (40.3 ± 21.0 vs 28.4 ± 15.3 mL/h/kg; p < 0.01). In children and adults comedicated with enzyme-inducing antiepileptic drugs (AEDs), topiramate CL/F values were approximately 1.5- to 2-fold higher than those observed in the absence of enzyme inducers, and the elevation in topiramate CL/F in children compared with adults was also present in the subgroups receiving enzyme inducers (66%; 76.6 ± 35.1 vs 46.1 ± 16.7 mL/h/kg; p < 0.0001). In the paediatric population, a negative correlation between CL/F and age was demonstrated, both in the absence (p < 0.01) and in the presence (p < 0.001) of enzyme induction. The independent influence of age and enzyme-inducing AEDs on topiramate CL/F was confirmed by multiple regression analysis.ConclusionTopiramate CL/F is highest in young children and decreases progressively with age until puberty, presumably due to age-dependent changes in the rate of drug metabolism. As a result of this, younger patients require higher dosages to achieve serum topiramate concentrations comparable with those found in older children and adults. Enzyme-inducing comedication decreases serum topiramate concentration by approximately one-half and one-third in children and adults, respectively.
ISSN:0312-5963
出版商:ADIS
年代:2005
数据来源: ADIS
|
6. |
Pharmacokinetic/Pharmacodynamic and Time-to-Event Models of Ribavirin-Induced Anaemia in Chronic Hepatitis C |
|
Clinical Pharmacokinetics,
Volume 44,
Issue 4,
2005,
Page 417-428
Michel Tod,
Muriel Farcy-Afif,
Jeanick Stocco,
Nathalie Boyer,
Valérie Bouton,
Martine Sinègre,
Patrick Marcellin,
Preview
|
PDF (342KB)
|
|
摘要:
BackgroundInterferon (IFN)-α and ribavirin combination therapy is the standard treatment for patients with chronic hepatitis C. However, ribavirin induces anaemia, especially by haemolysis, an adverse effect that is dose-limiting.ObjectivesThe aim of this study was to determine the relationships between ribavirin exposure and haemoglobin time-course, the time-to-anaemia and the covariates influencing these relationships in a population of patients treated for chronic hepatitis C. In addition, we also intended to establish a simple rule defining the need for dosage adjustment, using data obtained during the first month of treatment.MethodsA retrospective analysis of 99 patients treated with IFNα plus ribavirin, with known dosage administration history, liver biopsy, demographic data, red blood cell counts, haemoglobin level (1037 measurements, median 10 per patient, range 2–31) and serum creatinine during the entire treatment period (178 days, range 53–382 days) was conducted. The data were analysed by a pharmacokinetic/pharmacodynamic population model and Weibull time-to-anaemia model. The rule defining the need for dosage adjustment was as follows: adjustment was needed if haemoglobin at steady state (Hss), estimated by the Bayesian method based on data obtained during the first month of treatment, was <12 g/dL for men or <11 g/dL for women.ResultsIn both models, anaemia was related to the exposure of erythrocytes to ribavirin at time t (RT in mg/kg/day) by a maximum effect model, with RT50(dosage administration rate at which half the maximal effect is reached) approximately 12 mg/kg/day, and the significant covariates were initial haemoglobin level and bodyweight. Performances of a Bayesian prediction of Hssbased on two early haemoglobin level measurements were encouraging (mean prediction error 0.12 g/dL, precision 0.85 g/dL). The proposed rule for the need of dosage adjustment was able to predict the actual evolution of the dosage regimen in 76% of non-adapted patients and 69% of adapted patients.ConclusionThe current guidelines for ribavirin dosage administration, based on bodyweight, are adequate, at least in the 45–105kg range. Results indicate that Bayesian therapeutic monitoring could be helpful in controlling ribavirin-induced anaemia.
ISSN:0312-5963
出版商:ADIS
年代:2005
数据来源: ADIS
|
7. |
Absence of Pharmacokinetic Interactions of the Combined Contraceptive Vaginal Ring NuvaRing®with Oral Amoxicillin or Doxycycline in Two Randomised Trials |
|
Clinical Pharmacokinetics,
Volume 44,
Issue 4,
2005,
Page 429-438
Peter Dogterom,
Michiel W van den Heuvel,
Torben Thomsen,
Preview
|
PDF (277KB)
|
|
摘要:
BackgroundTwo pharmacokinetic studies were performed to investigate whether there is any interaction between etonogestrel or ethinylestradiol released from the combined contraceptive vaginal ring NuvaRing®and concomitant treatment with orally administered amoxicillin or doxycycline.MethodsIn one study, healthy women were randomised to receive either NuvaRing®alone for 21 days or NuvaRing®for 21 days plus amoxicillin on days 1–10. After a 7-day ring-free washout period, women were crossed over to the alternate regimen for a further 21-day treatment period. The other study used an identical design except that women received doxycycline instead of amoxicillin. The amoxicillin study measured serum etonogestrel and ethinylestradiol levels and area under the serum concentration-time curve (AUC) values over the initial 12 hours on days 1 (AUC12) and 10 (AUC216–228) and the whole of days 1–11 (AUC240) and 1–22 (AUC504). The doxycycline study measured AUC values over the initial 24 hours on days 1 (AUC24) and 10 (AUC216–240) and the whole of days 1–11 (AUC240) and 1–22 (AUC504).ResultsNo differences in etonogestrel or ethinylestradiol serum concentrations were observed between subjects using NuvaRing®alone versus those receiving the ring plus either of the antibiotics. Calculation of etonogestrel and ethinylestradiol interaction/control ratios confirmed the absence of pharmacokinetic interactions.ConclusionThe results from these studies demonstrate the absence of pharmacokinetic interactions between etonogestrel and ethinylestradiol released from NuvaRing®and the oral antibiotics amoxicillin and doxycycline, suggesting that contraceptive efficacy would also be unaffected.
ISSN:0312-5963
出版商:ADIS
年代:2005
数据来源: ADIS
|
8. |
Practical Guidelines to Interpret Plasma Concentrations of Antiretroviral DrugsThe Authors’ Reply |
|
Clinical Pharmacokinetics,
Volume 44,
Issue 4,
2005,
Page 439-440
Bregt S Kappelhoff,
Alwin D R Huitema,
Jos H Beijnen,
Preview
|
PDF (132KB)
|
|
ISSN:0312-5963
出版商:ADIS
年代:2005
数据来源: ADIS
|
|